Does the way artificial intelligence (AI) is used in pharma need to be reimagined? Irina Efimenko, chief executive of Russian analytics experts Semantic Hub, and Mike Samsonov, chief medical officer of R-Pharm, consider this question in an Expert View piece.
All-pervasive data
Nowadays, data is everywhere. The Harvard Business Review declared data scientists “who can coax treasure out of messy, unstructured data” to have the sexiest job of the 21st century1. New technologies are adopted faster and faster every year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze